Alembic Pharmaceuticals is currently trading at Rs. 684.55, up by 24.40 points or 3.70% from its previous closing of Rs. 660.15 on the BSE.
The scrip opened at Rs. 665.00 and has touched a high and low of Rs. 699.50 and Rs. 665.00 respectively. So far 24110 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 747.00 on 07-Oct-2015 and a 52 week low of Rs. 514.35 on 05-Feb-2016.
Last one week high and low of the scrip stood at Rs. 685.00 and Rs. 630.40 respectively. The current market cap of the company is Rs. 12787.03 crore.
The promoters holding in the company stood at 74.13%, while Institutions and Non-Institutions held 13.54% and 12.33% respectively.
Alembic Pharmaceuticals has received Establishment Inspection Report (EIR) from US Food & Drug Administration (USFDA). The regulator had carried out the inspection at the company's formulation facility located at Panelav in March, 2016.
Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907. The company manufactures and markets generic pharmaceuticals products all over the world.
